Earningsreport

Q4/2024 12/31/2024 EPS -0.250 ZacksConsensus -0.250 ActVsEst 0.000 - In-Line

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com